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Abstract 
Bioequivalence testing is one of the essential procedures used for marketing authorisation of veterinary 
medicinal products.The aim of this study was to implement a minimum set of statistical parameters in the 
bioequivalence assessment protocol of two anthelmintic formulas based on Triclabendazole (50 mg/mL) and 
Ivermectin (1 mg /mL), orally administered to sheep. The study can be synthesized to determine the relative 
bioavailability and bioequivalence of the two products on 36 clinically healthy sheep, following an 
unicentric, randomized, cross-over, two-sequence, two-treatment and 14-day wash-out study design. 
Determination of plasma concentrations of Triclabendazole sulfoxide and Ivermectin was made by two rapid, 
selective high performance liquid chromatography coupled with mass spectrometry (LC-MS/MS) methods. 
According to the implemented protocol, the statistical analysis of the data obtained corroborated a set of 
descriptive parameters (mean, standard deviation, interval) for the sample of subjects (age, weight) with 
pharmacokinetic parameters relevant for the active substances (Cmax, AUClast, AUCtot) with additional 
parameters (% extrapolated AUC, thalf, MRT) and drug safety (adverse events, clinical and laboratory 
screening and follow-up examinations). For bioequivalence assessment to all the primary pharmacokinetic 
parameters considered (Cmax, AUClast), a confidence interval of 90% for the ratio of the population means 
must be calculated. All these pharmacokinetic parameters were planned for analysis using ANOVA, after 
the data have been transformed (logarithmic transformation). A reference 90% confidence interval of 0.8 – 
1.25 was chosen. The bioequivalence can be concluded if the calculated 90% confidence interval around 
the ratio of means (Test/Reference) using log transformed data falls within the reference acceptance range 
of 0.8–1.25 for all primary pharmacokinetic parameters of triclabendazole sulfoxide and ivermectin. Finally, 
the bioequivalence of the two anthelmintic products and, respectively, the possibility of exchanging 
information between them in the veterinary therapeutic field is determined on the basis of the relevance of 
the values obtained in the statistical analyzes, especially of the pharmacokinetic parameters. 
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Introduction 
In bioequivalence studies, an analytical method approved by the international guides, well 
characterized and documented, must be used in order to obtain valid results (Cristina and Chirciu, 
2010). In this context, we should mention that the main characteristics of a performing and relevant 
bioanalytical method are selectivity, lower limit of quantification, calibration curve, accuracy, 
precision and stability (Cristea, 2005; Crivineanu, 2008). The main pharmacokinetic parameters 
analyzed in drug bioequivalence studies are the area under the curve (AUC), the maximum plasma 
concentration (Cmax) and the time taken to reach the maximum concentration (Tmax) (Crivineanu, 
2008; Palermo-Neto and Righi, 2008). Usually, Asc (0-t) and AUC (0-∞) are determined, but for 
the study of bioequivalence of the immediate release pharmaceutical forms, AUC (0-τ) is 
determined next to Cmax and Tmax. (Sargent and Chambers, 2009; Arion et al., 2015). Other 
additional parameters can be used in bioequivalence studies such as elimination constant (λz), half- 





concentrations in the predose must be detectable at 5% or less than Cmax (Vas et al., 2011; 
Valentina et al., 2007). 
The determination of Asc implies that the ratio between the two treatments applied is 
between 80-125% and in the case of Cmax and Cmin the confidence limits must be between 80 
and 125%. However, if the investigated parameters possess very high individual variability, the 
increase of the confidence interval between 70 and 143% is accepted, this being mentioned in the 
working protocol, together with a valid pharmacokinetic and pharmacodynamic justification 
(CVMP Guideline, 2012; Official Journal of the European Union - Directive 2010/63 / EU; 
International Committee for Harmonization, 2019). Such an increase in the confidence interval will 
not affect the effectiveness and safety of the product. In the case of antimicrobial and pesticide 
products, when defining the confidence interval, the risk of developing resistance to these 
substances will be taken into account (EMA / CVMP / 016/00-Rev.2, 2011; VICH GL52 
Bioequivalence; https: / /www.ema.europa). 
Statistical analysis allows the assessment of bioequivalence, based on the 90% confidence 
interval for the ratio between the population geometric means (test/reference) of the investigated 
parameters. The obtained data must be logarithmically transformed and analyzed in the ANOVA 
system. With this system, a confidence interval is then calculated for the differences between the 
two active formulas by logarithmic transformation, which will then be retransformed to the original 
scale, obtaining the desired ratio. 
Regarding the clinical impact of the active substances contained in the two products 
subjected to the bioequivalence test, we only mention the results of a study focused on evaluating 
the comparative efficacy of Ivermectin, Levamisol and Albendazole in natural infestations with 
gastrointestinal nematodes in goats (Aktaruzzaman et al., 2015). According to the results obtained 
in this study, in Bangladesh are predominantly evolving mixed parasitic infestations (given by 
Haemonchus spp., Trichostrongylus spp., Cooperia spp., Oesophagostomum spp., Trichuris spp., 
Strongyloides spp.), in which Ivermectin (A-mectin) predominate in Bangladesh, Levamisole 
(Levavet) and Albendazole (Almex-Vet) have proven to be effective and significantly reducing 
OPG (eggs per gram feces) in these gastrointestinal nematodes. Of the three products, Levavet has 
been shown to be more effective in the removal and remission of haematological parameters in 
goats. At the end of the study, it is estimated that the three anthelmintics have a major therapeutic 
impact, having ovocidal or egg production inhibiting effects in these gastrointestinal nematodes 
(Aktaruzzaman et al., 2015; Dupuy et al., 2010; Khalid et al., 2004). 
The aim of our study consisted of the statistical analysis of the pharmacokinetic parameters 
of triclabendazole sulfoxide and ivermectin, in order to evaluate the bioavailability and 
bioequivalence of a new anthelmintic formula under testing. The main objective of the research 
was focused on the formulation and testing of this new anthelmintic, with the mention that such a 
generic product has not been reported yet in ovine therapy. 
 
Materials and methods 
Subjects used in the test. The tests were performed on Țurcană sheep from the herd of a 
commercial micro-farm. According to the inclusion/exclusion criteria, a one-year sample of 
clinically healthy (no=36), non-lactating and non-lactating sheep, consisting of 26 females and 10 
males, was selected. The animals were selected 7 days before the start of the research, based on the 
inclusion criteria, including the physiological references for clinical and hemato-biochemical 
health parameters. The sheep were predominantly fed with good quality hay and corn and the water 





of the administration of the medicinal products and the administration of the water was suspended 
2 hours before and after the administration of the medication. In order to justify the size of the 
sheep sample, we should mention that the procedure for testing the bioequivalence of drugs 
requires the use of a significant sample of animals of the target species. 
General scheme of the study. The research protocol consisted of bioequivalence testing of 
two anthelmintic drug formulas based on Ivermectin and Triclabendazole: the reference product, 
Fasimec duo 50mg / ml + 1mg / ml oral suspension for sheep (Elanco Animal Health, UK), existing 
on the market and a novel product, Trimectin 50mg/ml + 1mg/ ml oral suspension for sheep 
(Pharma VIM Kft., Hungary) tested. The experimental procedure was adapted to the 
bioequivalence testing of the active molecules contained in the investigated products, as well as to 
sheep testing as the target species. In accordance with the requirements of the international 
guidelines, a unicentric, randomized, cross-type test was implemented, with two sequences, two 
treatments, with a single dose and a 14-day break between them. 
In the study 36 healthy clinical sheep were selected, in order to count on at least 30 eligible 
subjects at the end of the test. During the two periods of the study, the collection of serial blood 
samples was scheduled, under fasting conditions after the product administration. Venous blood 
samples (5 mL, on EDTA K3) were collected to evaluate the pharmacokinetic parameters strictly 
following the time intervals included in the protocol, the specific test times being distributed over 
a period of 480 hours after administration of the products. Thus, blood samples were collected at 
the following intervals: before administration (time 0.0) and at 0.5; 1.0; 1.5; 2.0; 3.0; 4.0; 6.0; 8.0; 
10.0; 12.0; 14.0; 16.0; 18.0; 20.0; 22.0; 24.0; 28.0; 36.0; 48.0; 72.0 96.0; 120.0; 144.0; 168.0; 
216.0; 264.0; 336.0; 408.0; 480.0 hours after dosing. After harvesting, the samples were 
centrifuged, at 5000 rpm, for 10 minutes, and the plasma was separated into two tubes. Plasmas 
were transported and stored at -20 ° C and plasma concentrations of triclabendazole sulfoxide and 
ivermectin were determined by high performance liquid chromatographic method coupled with 
mass spectrometry (LC-MS / MS). At the beginning and the end of the test, the main hemato- 
biochemical parameters necessary for the evaluation of the health status were investigated. The 
study plan is finalized with the bioequivalence evaluation of the test and reference formulas, based 
on the analysis of the primary pharmacokinetic parameters (Cmax and ASC0-t) of ivermectin and 
triclabendazole sulfoxide. 
Statistical analysis of pharmacokinetic parameters. In the final assessment of the 
bioequivalence were included the data obtained in the testing of the entire sheep sample, because 
none of the 36 subjects was excluded from the test. 
Pharmacokinetic parameters were analyzed by a non-compartmental method, for both 
triclabendazole sulfoxide and ivermectin. The bioequivalence assessment of the primary 
pharmacokinetic parameters (Cmax and AUClast) also included the quantification of a 90% 
confidence interval for the Test/Reference module. These pharmacokinetic parameters were 
determined after logarithmic data transformation, using the ANOVA system. 
The reference values for the 90% confidence interval were set in the range 0.8-1.25. At the 
same time, a series of usual statistical parameters were calculated: arithmetic mean, harmonic 
mean, geometric mean, SEM, standard deviation, median. In order to compare the values obtained 
at the Tmax parameter, nonparametric tests were performed, using the non-transformed data 
(KruskalWallis and Friedman's test) and for the calculation of the average Waiting Time (TMA) 
and the Half Time (T1/2), the ANOVA system was applied. Pharmacokinetic analyzes were based 





In order to evaluate the possible statistical and clinical significance of pharmacokinetic 
interactions, the variance of the main calculated pharmacokinetic parameters was used, using a 
linear statistical calculation model for the subject and treatment variables. 
 
Results and discussions 
The relevance of the analysis of the plasma samples, prepared during the study was ensured 
by the LC-MS method, which was previously validated by an authorized laboratory (of the Vim 
Spectrum Company). The results of the pharmacokinetic analyzes of the plasma samples provided 
a set of data compliant with the current guidelines. 
The analysis of these data revealed that between the plasma concentrations recorded at the 
initial assessments and those obtained at the final evaluations, no differences higher than 20% 
compared to the average values were found, in the case of 74% of the samples for triclabendazole 
and 84% of the samples for ivermectin. Equally relevant was the analysis of the distribution of the 
curves of average plasma concentrations recorded for the two active substances (triclabendazole 
sulfoxide and ivermectin) in the composition of the test and reference products (Fig. 1). 
Framed in the same context, the evolution of average Cmax values revealed reaching levels 
of 56.0 (+/- 17.1) μg/mL for the test product and 54.4 (+/- 20.1) μg/mL for the reference product, 
regarding triclabendazole. For ivermectin, however, lower mean Cmax values were found, namely 
41.2 (+/- 8.7) ng/mL for the test product and 42.2 (+/- 10.5) ng / mL for the reference product. 
There are also noteworthy the data obtained from data processing through the ANOVA 
system, which revealed the evolution of 90% confidence intervals of the Test/Reference ratio for 
Cmax (highest concentrations), of 0.98-1.12 for triclabendazole and 0, 92-1.05 for ivermectin. 
In the same context, 90% confidence intervals for triclabendazole and ivermectin are also 
integrated regarding the ratio between the Test and Reference product for AUC, to the last 
measurable concentration (AUClast), indicating values of 0.88-1.07 for triclabendazole sulfoxide 
and 0.86-1.06 for ivermectin. 
The distribution of mean values and statistics of the pharmacokinetic parameters for 
triclabendazole sulfoxide and ivermectin are presented in Table 1. 
 
a b 
Fig. 1. Curves of mean plasma concentrations of Triclabendazole sulfoxide (a) and Ivermectin (b) during 





As it appears from the analysis of the obtained results, all the 36 selected subjects were 
eligible for the pharmacokinetic evaluation and the completion of the testing process. Therefore, 
all the subjects coressponded with the requirements set out in the experimental protocol and 
implicitly, with the provision of data for the evaluation of the pharmacokinetics of the active 
substances introduced in the testing. As a consequence, the products subjected to the 
bioequivalence test were administered to all the subjects introduced into the study and they were 
used during two periods, which indicated the achievement of the maximum level of compliance. 
We also note that no deviation from the protocol requirements has been recorded and no 
adverse effects or manifestations have been reported. These achievements were revealed by the 
predominant classification of the physiological parameters, evaluated at the clinical and 
paraclinical examinations, in the physiological limits of the species, indicating that the study did 
not affect the health status of the animals subjected to testing. 
The results obtained in the clinical and paraclinical evaluations also highlighted that, 
compared to the two single doses of triclabendazole and ivermectin, administered orally, as well 
as the inherent stress associated with the application of the experimental procedures, the 
investigated sheep showed a high level of tolerance. 
It is important to underline the outstanding performance of the LC-MS/MS method used 
in order to determine the plasma concentrations of triclabendazole sulfoxide and ivermectin, which 
was initially evaluated and validated in-house. 
According to the data obtained at the re-analysis of plasma concentrations, this 
bioequivalence test met the current legislative standards regarding the validation of the 
bioanalytical methods (Lainesse et al., 2012; Nation and Sansom, 1994), because the percentage 
difference between the values obtained at the initial and final analyzes were within the range of +/- 
20% of their average, for more than 67% of the tested samples in the case of triclabendazole 
sulfoxide and ivermectin. 
The relevance of the values obtained in the calculation of the primary pharmacokinetic 
parameters (Cmax, Tmax, AUClast) was also confirmed by the values obtained when quantifying 
the 90% confidence interval of the T/R ratio of the pharmacokinetic mean, as well as the 
significance of the difference of the Tmax values recorded in the Friedman și Kruskal-Wallis tests. 
 
Table 1. Descriptive statistical values of the primary, secondary and additional pharmacokinetic 






TEST PRODUCT REFERENCE PRODUCT 
Mean GeoMean St. Dev. Mean GeoMean St. Dev. 
Triclabendazole sulfoxide 
Cmax (ng/ml) 36 55.997 53.409 17.124 54.402 50.808 20.1 
Tmax (h) 36 11.583 10.184 5.6334 11.833 10.957 4.6935 
AUClast (ng/ml*h) 36 1655.6 1592.1 443.85 1803.3 1642.9 750.6 
AUCtot (ng/ml*h) 36 1702.4 1640.3 445.88 1847.7 1691 755.64 
%AUCextra 36 2.9218 2.4573 2.0036 2.8269 2.4212 1.9826 
T1/2 (h) 36 15.517 15.14 3.7018 15.594 15.234 3.5047 






Cmax (ng/ml) 36 41.22 40.301 8.6637 42.182 41.067 10.462 
Tmax (h) 36 17.5 17.047 4.0107 18.333 17.61 5.6061 
AUClast (ng/ml*h) 36 3804.3 3562.4 1295.3 3926.9 3719.3 1310.5 
AUCtot (ng/ml*h) 36 4001 3754.4 1338.7 4172.6 3952.9 1389.2 
%AUCextra 36 5.0776 4.6054 2.563 5.88 5.3701 2.3993 
T1/2 (h) 36 84.295 79.574 27.945 91.045 87.29 27.042 
MRT (h) 36 118.36 113.94 30.72 124.97 121.44 29.278 
 
Synthetically expressed, the values of the 90% confidence intervals recorded for the T/R 
ratio of triclabendazole and ivermectin were within the conventional range of drug bioequivalence, 
comprised between 80 and 125% for all primary parameters, the differences recorded in the Tmax 
(in the Friedman and Kruskal-Wallis tests) being devoid of statistical significance for both active 
substances. 
Summarizing the above data, we can consider that all the requirements of the current 
legislation, in the field of drug bioequivalence testing have been fulfilled, in order to establish that 
the investigated products are bioequivalent. In order to explain the achieved level of 
bioequivalence, we resort to a detailed presentation of the results obtained in correlation with those 
reported by other researchers in the field. Therefore, following the evaluation of the bioequivalence 
on 36 complete data sets and the evolutionary analysis of plasma concentrations, we revealed a 
high degree of similarity between the primary pharmacokinetic parameters of triclabendazole 
sulfoxide and ivermectin, determined after oral administration of the test and reference products. 
Specifically, for triclabendazole sulfoxide the average bioequivalence of the Test/Reference (T/R) 
ratio was 1.05119 for Cmax and 0.969058 for AUClast, and the 90% confidence intervals (Test / 
reference ratio) were 98,276 - 112.44% for Cmax and 87,971 - 106.75% for AUClast. We also 
found similar data in the case of ivermectin, the average bioequivalence being 0.981343 for Cmax 
and 0.957828 for AUClast, and the 90% confidence intervals of 92.099 - 104.57% for Cmax and 
86.26 - 106.36 % for AUClast. 
According to the current legislation, if during the course of the bioequivalence studies of 
the veterinary medical products, the concentration in the predose is less than 5% or equal to 5% of 
the Cmax value of the tested subject, its values can be included without changes in all 
measurements and pharmacokinetic calculations (EMA Guide / CVMP / 016/00-Rev.2, 2011). 
Similar data revealed the analysis of the results obtained in the Kruskal Wallis and Friedmanan 
tests, which did not show statistically significant differences between the values recorded in the 
test and reference products, in terms of the evolution of Cmax and AUClast values. In addition to this, 
if different distributions and important variations of the statistical data appear in the bioequivalence 
studies, it is necessary to use novel statistical methods, especially in the category of the non- 
parametric ones, as the international guides in the field foresee (EMA/CVMP/016/00-Rev.2, 2011; 
VICH GL52 Bioequivalence; https://www.ema.europa). On the other hand, if the plasma levels of 
the test product were higher than that of the reference product, the status of the reference formula 
would be uncertain. In such cases, it is usually necessary to increase the number of animals 
subjected to the research. We also recall that, in the case of drugs with very variable values, we can 





in accordance with the requirements of the ethics committee, if the coefficient of variation is over 
30% and if the ratio of the geometric mean is between 0.8 and 1.25. 
Synthesizing the data obtained in our study, in comparison with the legal requirements, all 
the requirements for establishing the bioequivalence of the two products were fulfilled, without the 
need to supplement the number of animals. 
 
Conclusions 
Finally, based on the results obtained in this research, we conclude that the TEST product, 
Trimectin 50 mg / mL + 1 mg / mL oral suspension for sheep (Pharma VIM Ltd.) is bioequivalent 
to the REFERENCE product, Fasimec Duo 50 mg / mL + 1 mg / mL oral suspension for sheep 
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